Skip to content
Clear Spin Group

Individuals Discontinuing Weight-Loss Injections Put On Pounds Far More Rapidly Compared to Those on Conventional Diets

Image of pharmaceutical injection and weighing machine
Obesity treatment often requires ongoing approaches.

A recent study suggests that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who stop traditional diet and exercise regimens.

Findings released in a prominent health publication points out that while overweight individuals can lose substantial amounts of their body weight while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.

"Individuals using these medications must be informed of the risk of fast rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.

Such speed of recovery means a reversion to pre-treatment mass within about one and a half years.

Comparing Treatments

The analysis, which reviewed dozens of studies involving over 9,000 of participants, contrasted the effects of the injectable medications with other pills.

Researchers point out that individuals who shed pounds through dieting usually experience a more gradual creep back—approximately 100 grams monthly—post-intervention.

The Reason for the Fast Regain

Nutrition scientists propose the way of the jabs accounts for the heightened rebound.

GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which controls hunger.

"Sustained high doses of the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its own natural GLP-1, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.

"Stopping of this GLP-1 'fix' means hunger is no longer kept in check, making binge eating much more probable."

A Lifelong Issue?

Health authorities recommend the injections for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.

Professionals contend that, due to the high risk of weight regain, the therapy might need to be ongoing.

This view is reinforced by pharmaceutical companies, who say that the findings "emphasize the persistent nature of excess weight," similar to managing diseases like high blood pressure.

Patient Experiences

Individuals who have stopped the jabs describe a powerful resurgence of hunger.

"It was like a switch flipping and you become ravenous," said one woman.

This challenge is compounded if patients have not developed lasting lifestyle or habit changes during therapy.

Significant Interest

Figures indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with demand being substantial.

  • Adoption is more common among women than males.
  • The middle-aged age group shows the greatest level of interest.
  • Many access the medications through private prescriptions rather than public health services.

In conclusion, researchers emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone cure and long-term success hinges on integrated behavioural support.

By

Sonya Hall

Maya Chen is a seasoned business strategist with over 15 years of experience in market analysis and corporate consulting.

Clear Spin Group

Type to search articles.